AIM

AIM ImmunoTech Inc

0.1800

Oct 02 • 3:59 PM ET -0.0077 (-4.10%)

0.1859

Aftermarket • 7:56 PM ET +0.0059 (3.28%)

Healthcare Biotechnology USA Nano AMEX

Oct 01, 9:05 AMAIM ImmunoTech completes final Ampligen dosing in Phase 2 DURIPANC metastatic pancreatic cancer trial, topline data expected in the first quarter of 2027

Peers: APRE BCDA BIVI GOVX KAPA KPRX LNAI CALC CVM NEUP

Scroll to Statements

Index	-
Market Cap	7.05M
Enterprise Value	1.01M
Income	-14.27M
Sales	0.10M
Book/sh	0.27
Cash/sh	0.25
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	19
IPO	Jul 15, 1996

P/E	-
Forward P/E	-
PEG	-
P/S	70.50
P/B	0.67
P/C	0.71
P/FCF	-
EV/EBITDA	-
EV/Sales	10.10
Quick Ratio	2.11
Current Ratio	2.11
Debt/Eq	0.51
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-3.84
EPS next Y	-0.54
EPS next Q	-0.14
EPS this Y	90.02%
EPS next Y	37.21%
EPS next 5Y	58.64%
EPS past 3/5Y	40.27% 28.21%
Sales past 3/5Y	-14.54% -11.60%
EPS Y/Y TTM	84.62%
Sales Y/Y TTM	-21.49%
EPS Q/Q	93.98%
Sales Q/Q	4.00%
Earnings	Aug 10 BMO
EPS/Sales Surpr.	-152.94% -

Insider Own	5.10%
Insider Trans	3.25%
Inst Own	2.93%
Inst Trans	2.95%
ROA	-169.28%
ROE	-2382.30%
ROIC	-183.30%
Gross Margin	-726.32%
Oper. Margin	-11148.42%
Profit Margin	-15021.05%
SMA20	-13.07%
SMA50	-22.74%
SMA200	-70.13%
Trades

Shs Outstand	39.18M
Shs Float	37.18M
Short Float	7.44%
Short Ratio	0.59
Short Interest	2.77M
52W High	2.88 -93.74%
52W Low	0.17 8.50%
Volatility	7.73% 6.19%
ATR (14)	0.02
RSI (14)	33.69
Beta	1.31
Rel Volume	0.28
Avg Volume	4.69M
Volume	1,331,540

Perf Week	-5.31%
Perf Month	-23.27%
Perf Quarter	-39.39%
Perf Half Y	-69.75%
Perf YTD	-84.05%
Perf Year	-93.20%
Perf 3Y	-99.60%
Perf 5Y	-99.91%
Perf 10Y	-100.00%
Recom	1.00
Target Price	4.25
Prev Close	0.19
Price	0.18
Change %	-4.10%

Oct-01-26 09:02AM	AIM ImmunoTech Spotlights Growing Attention Around Ampligen Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data (GlobeNewswire) +7.26%
Sep-30-26 08:44AM	AIM ImmunoTech Discusses Ampligen's Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video (GlobeNewswire)
Sep-22-26 08:55AM	AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib (GlobeNewswire)
Sep-09-26 09:03AM	AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen in Pancreatic Cancer in New CEO Corner Video (GlobeNewswire)
Sep-02-26 08:43AM	AIM ImmunoTech Significantly Expands Ampligen Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 (GlobeNewswire)
08:51AM	Loading…
Aug-31-26 08:51AM	AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen) Used in Combination with Pembrolizumab (Keytruda), Expanding Oncology IP Protection for Ampligen Through 2039 (GlobeNewswire) -12.54%
Aug-27-26 09:01AM	AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference (GlobeNewswire)
Aug-12-26 08:44AM	AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published 'Breaking Defense' Article (GlobeNewswire)
Aug-10-26 08:36AM	AIM ImmunoTech Reports Second Quarter 2026 Financial Results and Highlights Significant Operational Execution Advancing Ampligen Toward Planned Phase 3 Development in Pancreatic Cancer (GlobeNewswire) -7.85%
Aug-03-26 08:33AM	AIM ImmunoTech Ahead of Schedule on 'Last Dose' DURIPANC Critical Clinical Inflection Point (GlobeNewswire)
Jul-07-26 09:03AM	AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program (GlobeNewswire)
Jun-24-26 08:29AM	AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones (GlobeNewswire)
Jun-22-26 08:45AM	AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series (GlobeNewswire)
Jun-18-26 09:01AM	AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer (GlobeNewswire) -5.02%
Jun-15-26 08:01AM	AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency (GlobeNewswire)
09:29AM	Loading…
Jun-09-26 09:29AM	AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules (GlobeNewswire) -22.34%
Jun-08-26 08:33AM	AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire)
Jun-04-26 08:55AM	AIM ImmunoTech Releases Virtual Investor 'What This Means' Video Segment Discussing Ampligen's Potential in Ebola Virus Disease Preparedness (GlobeNewswire) -19.22%
Jun-01-26 10:19AM	AIM Stock Soars Over 200% As Pancreatic Cancer Trial Hits Enrollment Milestone Early CEO Sees 'Value-Inflection Period' Ahead (Stocktwits) +120.35%
10:19AM	AIM Stock Soars 42% As Pancreatic Cancer Trial Hits Key Enrollment Milestone Before Schedule CEO Sees 'Significant Value-Inflection Period' Ahead (Stocktwits)
08:58AM	AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones (GlobeNewswire)
May-27-26 08:47AM	AIM ImmunoTech Announces Emerging Ebola Opportunity for Ampligen Amid Escalating Global Health Concerns and WHO Emergency Declaration (GlobeNewswire) +72.37%
May-20-26 03:02PM	AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement (GlobeNewswire) -38.42%
May-19-26 08:02AM	AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities (GlobeNewswire)
May-14-26 08:41AM	AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer (GlobeNewswire)
May-08-26 08:40AM	AIM ImmunoTech, Inc. Announces Exercise of Warrants for Approx. $4.2 Million in Gross Proceeds (GlobeNewswire) -39.66%
May-07-26 08:23AM	AIM ImmunoTech Announces 50% Objective Response Rate (ORR) in UPMC Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential (GlobeNewswire) +16.42%
Apr-16-26 09:00AM	AIM ImmunoTech Enters Pivotal Value Inflection Phase with Planned Phase 3 Study of Ampligen in Pancreatic Cancer, Backed by Positive Clinical Signals, Orphan Drug Status, and Global IP (GlobeNewswire)
Apr-13-26 06:00PM	AIM ImmunoTech Provides Routine Update on Annual Filings (GlobeNewswire) +8.95%
Apr-09-26 08:00AM	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event (GlobeNewswire) -6.24%
08:36AM	Loading…
Mar-18-26 08:36AM	AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors (GlobeNewswire) +43.66%
Mar-06-26 07:00PM	AIM ImmunoTech Announces Closing of its Rights Offering (GlobeNewswire) +8.33%
Mar-04-26 09:00AM	AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million (GlobeNewswire)
Mar-02-26 09:00AM	AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer (GlobeNewswire) -14.89%
Feb-27-26 09:00AM	AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering (GlobeNewswire) -8.32%
Feb-25-26 09:00AM	AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 (GlobeNewswire)
Feb-23-26 08:55AM	AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer (GlobeNewswire)
Feb-12-26 04:35PM	CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -6.36% +58.23%
08:55AM	AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event (GlobeNewswire)
Feb-11-26 08:30AM	AIM ImmunoTech Announces Commencement of Rights Offering (GlobeNewswire) -13.51%
Feb-06-26 08:55AM	AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial (GlobeNewswire) -7.32%
Feb-05-26 08:40AM	AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) +16.59%
Jan-28-26 09:40AM	Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? (Zacks)
Jan-27-26 04:35PM	AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire)
Jan-23-26 01:22PM	AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering (GlobeNewswire) -5.16%
Jan-08-26 09:40AM	Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-30-25 05:10PM	AIM ImmunoTech Announces Stock Dividend (GlobeNewswire) -10.32%
Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-10-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire)
Dec-01-25 08:55AM	AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series (GlobeNewswire)
Nov-18-25 08:55AM	AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program (GlobeNewswire) -7.64%
Nov-10-25 08:55AM	AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer (GlobeNewswire) -6.37%
Nov-04-25 09:05AM	AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting (GlobeNewswire) -20.40%
Nov-03-25 08:55AM	AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue (GlobeNewswire)
Oct-23-25 08:51AM	Zacks.com featured highlights include The Honest Company, Dutch, AIM ImmunoTech, Masimo and Cognizant Technology Solutions (Zacks)
Oct-22-25 12:02PM	Bet On 5 Top-Ranked Stocks With Rising P/E (Zacks)
Oct-20-25 09:15AM	AIM ImmunoTech to Attend the 2025 Maxim Growth Summit (GlobeNewswire)
Oct-10-25 12:00PM	All You Need to Know About AIM ImmunoTech (AIM) Rating Upgrade to Buy (Zacks)
Sep-25-25 08:45AM	AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors (GlobeNewswire)
Sep-22-25 09:00AM	AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth (GlobeNewswire) +6.16%
Sep-21-25 09:10AM	Maxim Group Sees 133% Upside in AIM ImmunoTech Inc. (AIM) (Insider Monkey)
Sep-04-25 11:00AM	AIM ImmunoTech Highlights Growing Body of Compelling Data of Ampligen for the Treatment of Pancreatic Cancer at Conference in Poland (GlobeNewswire)
Aug-21-25 09:00AM	AIM ImmunoTech Announces Release of the Next CEO Corner Segment (GlobeNewswire) +8.47%
Aug-15-25 09:00AM	AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-14-25 08:55AM	AIM ImmunoTech to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire)
Aug-11-25 06:55PM	FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-06-25 09:00AM	AIM ImmunoTechs Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
09:00AM	AIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025) (GlobeNewswire)
Aug-04-25 09:00AM	AIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen Clinical Development Toward Pancreatic Cancer Approval (GlobeNewswire) +6.36%
Jul-31-25 09:00AM	AIM ImmunoTech Announces Closing of $8.0 Million Public Offering (GlobeNewswire)
Jul-29-25 09:00AM	AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering (GlobeNewswire) -56.25%
Jul-28-25 09:00AM	AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen (rintatolimod) in Combination with AstraZeneca's Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer (GlobeNewswire) -14.29%
Jul-02-25 08:55AM	AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies (GlobeNewswire)
Jun-20-25 04:15PM	AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements (GlobeNewswire) +10.96%
Jun-17-25 08:55AM	AIM ImmunoTech Resumes Trading on NYSE American (GlobeNewswire) +6.84%
Apr-07-25 01:26PM	AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market (GlobeNewswire) -57.53%
Apr-04-25 04:45PM	AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal (GlobeNewswire) -19.37%
Mar-27-25 08:05AM	AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

CEOThomas Kenwood Equels

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Equels Thomas K	CEO & President	Sep 17 '26	Buy	0.21	24,000	4,992	126,822	Sep 18 08:30 AM
Equels Thomas K	CEO & President	Sep 16 '26	Buy	0.21	11,000	2,310	102,822	Sep 17 12:01 PM
Equels Thomas K	CEO & President	Sep 15 '26	Buy	0.22	22,000	4,862	91,822	Sep 16 09:15 AM
Equels Thomas K	CEO & President	Sep 14 '26	Buy	0.22	5,900	1,292	69,822	Sep 15 04:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIM

AIM ImmunoTech Inc

Upgrade your Finviz experience